Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1129
Shown on this page
12
Current sort
Recently updated
Campus scope
Northwestern Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Northwestern Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 829–840 of 1,129 matching trials with a site at Northwestern Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression

NCT07610655
Status at this site: Recruiting
View directory record Official record
Conditions
Post Operative Delirium, Cognitive Impairment, Vagus Nerve Stimulation, Depression
Interventions
Transcutaneous vagal nerve stimulation, Sham (No Treatment)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting No phase listed Observational

Chronic Pain in Rheumatoid Arthritis

NCT05038553
Site status not listed — check the official record
View directory record Official record
Conditions
Arthritis, Rheumatoid, Pain
Interventions
No intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Not applicable Interventional

Effect of Duramesh™ on Hernia Formation After Ileostomy Closure

NCT06511414
Site status not listed — check the official record
View directory record Official record
Conditions
Incisional Hernia, Ileostomy - Stoma
Interventions
duramesh, Control
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Not applicable Interventional

Combining MyoCI With Memory Reactivation to Improve Motor Recovery After Stroke

NCT04312269
Status at this site: Recruiting
View directory record Official record
Conditions
Stroke
Interventions
Targeted Memory Reactivation (TMR)
Other
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Systems Biology of Early Atopy

NCT04798079
Site status not listed — check the official record
View directory record Official record
Conditions
Allergic Diseases, Food Allergy, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2032
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Test of Target Engagement of Ambiguity Aversion

NCT06962527
Status at this site: Recruiting
View directory record Official record
Conditions
Intolerance of Uncertainty, Anxiety, Intolerance of Uncertainty; Anxiety, Depression, Anxiety
Interventions
Uncertainty-focused single session intervention, Maintaining a healthy lifestyle single session intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
25 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting No phase listed Observational

Northwestern Neuromuscular Disease Biorepository

NCT07477509
Status at this site: Recruiting
View directory record Official record
Conditions
Neuromuscular Diseases (NMD)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2050
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Early Phase 1 Interventional

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

NCT06684522
Status at this site: Recruiting
View directory record Official record
Conditions
Eyelid Dermatitis
Interventions
Upadacitinib 15 MG
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Recruiting Phase 2 Interventional

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

NCT05620771
Status at this site: Recruiting
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
7
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:49 PM EDT
Active, not recruiting Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial

NCT05656560
Site status not listed — check the official record
View directory record Official record
Conditions
Polypharmacy
Interventions
Clinical decision support (CDS)-Commitment nudge, Clinician education, Clinical decision support (CDS)-Justification nudge
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 1:49 PM EDT

About this Northwestern Medicine institution page

What this page lists
ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Northwestern University at any site, browse by condition, or browse by U.S. city.